Evidence map›Paper›PMID 30429088›Full record

ArticleEBioMedicine2018

SRSF1 modulates PTPMT1 alternative splicing to regulate lung cancer cell radioresistance.

Junxiu Sheng, Qingzhi Zhao, Jinyao Zhao, Wenjing Zhang, Yu Sun, Pan Qin, Yuesheng Lv, Lu Bai, Quan Yang, Lei Chen and 13 more

Open access · goldAbstract read
In one paragraph

Article in EBioMedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 1 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 1 synthesis or guideline pooled it, 168 citations in OpenAlex.

  1. Alternative splicing and cancer: a systematic review.Signal transduction and targeted therapy · 2021
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Role of alternative splicing in cancer progression.Irish journal of medical science · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. XRCC1 is linked to poor prognosis in adenocarcinoma of the esophagogastric junction after radiotherapy: transcriptome and alternative splicing events analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. The translatome of glioblastoma.Molecular oncology · 2025
    Article
  16. Article
  17. Article
  18. Tumor-promoting effect and tumor immunity of SRSFs.Frontiers in cell and developmental biology · 2025
    Review
  19. Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 3 countries.

Junxiu ShengDepartment of Radiation Oncology, First Affiliated Hospital, Dalian Medical University, Dalian 116044, China.
Qingzhi ZhaoInstitute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China.
Jinyao ZhaoInstitute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China.
Wenjing ZhangInstitute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China. Electronic address: zhangwj@dmu.edu.cn.
Yu SunInstitute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China.
Pan QinFaculty of electronic information and electrical engineering, Dalian university of Technology, Dalian 116001, China.
Yuesheng LvInstitute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China.
Lu BaiInstitute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China.
Quan YangInstitute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China.
Lei ChenInstitute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China.
Yangfan QiInstitute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China.
Ge ZhangDepartment of Immunology, Dalian Medical University, Dalian 116044, China.
Lin ZhangInstitute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China.
Chundong GuDepartment of Thoracic Surgery, First Affiliated Hospital, Dalian Medical University, Dalian 116044, China.
Xiaoqin DengDepartment of Radiation Oncology, First Affiliated Hospital, Dalian Medical University, Dalian 116044, China.
Han LiuInstitute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China.
Songshu MengInstitute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China.
Hong GuFaculty of electronic information and electrical engineering, Dalian university of Technology, Dalian 116001, China.
Quentin LiuInstitute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China.
Judy M CoulsonCellular & Molecular Physiology Department, University of Liverpool, UKL69 3BX, UK.
Xiaoling LiSignal Transduction Laboratory, NIEHS, RTP, NC 27709, USA.
Bing SunDepartment of Thoracic Surgery, First Affiliated Hospital, Dalian Medical University, Dalian 116044, China. Electronic address: dysunbing@163.com.
Yang WangInstitute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China. Electronic address: yangwang@dmu.edu.cn.
Dalian Medical University · CNDalian University · CNNational Institute of Environmental Health Sciences · USUniversity of Liverpool · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRadioresistance is the major cause of cancer treatment failure. Additionally, splicing dysregulation plays critical roles in tumorigenesis. However, the involvement of alternative splicing in resistance of cancer cells to radiotherapy remains elusive. We sought to investigate the key role of the splicing factor SRSF1 in the radioresistance in lung cancer.

methodsLung cancer cell lines, xenograft mice models, and RNA-seq were employed to study the detailed mechanisms of SRSF1 in lung cancer radioresistance. Clinical tumor tissues and TCGA dataset were utilized to determine the expression levels of distinct SRSF1-regulated splicing isoforms. KM-plotter was applied to analyze the survival of cancer patients with various levels of SRSF1-regulated splicing isoforms.

findingsSplicing factors were screened to identify their roles in radioresistance, and SRSF1 was found to be involved in radioresistance in cancer cells. The level of SRSF1 is elevated in irradiation treated lung cancer cells, whereas knockdown of SRSF1 sensitizes cancer cells to irradiation. Mechanistically, SRSF1 modulates various cancer-related splicing events, particularly the splicing of PTPMT1, a PTEN-like mitochondrial phosphatase. Reduced SRSF1 favors the production of short isoforms of PTPMT1 upon irradiation, which in turn promotes phosphorylation of AMPK, thereby inducing DNA double-strand break to sensitize cancer cells to irradiation. Additionally, the level of the short isoform of PTPMT1 is decreased in cancer samples, which is correlated to cancer patients' survival.

conclusionsOur study provides mechanistic analyses of aberrant splicing in radioresistance in lung cancer cells, and establishes SRSF1 as a potential therapeutic target for sensitization of patients to radiotherapy.

Indexed as

Alternative SplicingGene Expression Regulation, NeoplasticAMP-Activated Protein KinasesAnimalsCell Line, TumorComputational BiologyDisease Models, AnimalDNA Breaks, Double-StrandedGene Expression ProfilingHumansLung NeoplasmsMiceProtein Tyrosine PhosphatasesPTEN PhosphohydrolaseRadiation ToleranceSerine-Arginine Splicing FactorsAMP-Activated Protein KinasesProtein Tyrosine PhosphatasesPTEN PhosphohydrolasePtpmt1 protein, humanSerine-Arginine Splicing FactorsSRSF1 protein, humanAlternative splicingAMPKPTPMT1Radio-resistanceSRSF1

Identifiers

PMID30429088
PMCPMC6306353
OpenAlexW2900563804

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.